​

ImageneBio Stock (NASDAQ:IMA)

ForecastOwnershipFinancialsChart
ImageneBio by TradingView

Previous Close

$5.51

52W Range

$3.94 - $18.00

50D Avg

$5.60

200D Avg

$6.96

Market Cap

$64.40M

Avg Vol (3M)

$347.94K

Beta

0.72

Div Yield

-

IMA Company Profile

ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

10

IPO Date

Feb 27, 1998

Website

IMA Performance

IMA Financial Summary

Dec 25Dec 24Dec 23
Revenue-$3.50M$9.16M
Operating Income$-48.45M$-37.00M$-75.42M
Net Income$-52.40M$-36.57M$-68.17M
EBITDA$-48.45M$-35.47M$-74.40M
Basic EPS-$-1.02$-1.63
Diluted EPS-$-1.02$-1.63

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
KLRSKalaris Therapeutics Inc
QNCXQuince Therapeutics, Inc.
ARTVArtiva Biotherapeutics, Inc.
MGXMetagenomi, Inc. Common Stock
IFRXInflaRx N.V.
STROSutro Biopharma, Inc.
CNTXContext Therapeutics Inc.
CNTBConnect Biopharma Holdings Limited
OVIDOvid Therapeutics Inc.
STTKShattuck Labs, Inc.